HBIO Harvard Bioscience Inc.

Harvard Bioscience to Present at Benchmark Company’s Discovery One-On-One Investor Conference on December 7, 2023

Harvard Bioscience to Present at Benchmark Company’s Discovery One-On-One Investor Conference on December 7, 2023

HOLLISTON, Mass., Nov. 20, 2023 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced it will be presenting at the Benchmark Company 12th Annual Discovery One-on-One Investor Conference to be held Thursday December 7th, 2023 at the New York Athletic Club in New York City.

The conference offers emerging growth and dynamic publicly traded companies access to institutional and individual investors in a unique one-on-one format during which Jim Green, Chairman and Chief Executive Officer, will be participating in one-on-one meetings with investors and analysts throughout the day. Joining him will be Jennifer Cote, the company’s Chief Financial Officer and Treasurer.

To schedule a one-on-one meeting with Harvard Bioscience, Inc., you may submit your request online via the link provided upon registration. To register for the conference, please visit

About Harvard Bioscience

Harvard Bioscience, Inc. is a leading developer, manufacturer and seller of technologies, products and services that enable fundamental advances in life science applications, including research, pharmaceutical and therapy discovery, bio-production and preclinical testing for pharmaceutical and therapy development. Our customers range from renowned academic institutions and government laboratories to the world’s leading pharmaceutical, biotechnology and contract research organizations. With operations in North America, Europe, and China, we sell through a combination of direct and distribution channels to customers around the world.

Investor Inquiries:



(508) 893-3120

About The Benchmark Company

The Benchmark Company is an institutionally focused, research driven, sales trading and investment banking firm. We were founded in 1988 and are headquartered in New York City. Our focus is on fostering the long-term success of our corporate clients through raising capital, providing strategic advisory services, generating insightful research, and developing institutional sponsorship by leveraging the firm’s sales, trading, and equity research capabilities.

.



EN
20/11/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Harvard Bioscience Inc.

 PRESS RELEASE

Harvard Bioscience, Inc. to Present and Host One-on-One Meetings at th...

Harvard Bioscience, Inc. to Present and Host One-on-One Meetings at the 14th Annual East Coast IDEAS Conference on June 12, 2024 HOLLISTON, Mass., June 06, 2024 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that Jim Green, Chairman and Chief Executive Officer, and Jennifer Cote, Chief Financial Officer, will be presenting to investors at the 14th Annual East Coast IDEAS Conference at the Jay Conference Center – Bryant Park in New York City on June 12, 2024. The Company’s presentation is scheduled for 2:45-3:20 PM ET on June 12th. The Company will also host o...

 PRESS RELEASE

Harvard Bioscience, Inc. to Present at the Jefferies Global Healthcare...

Harvard Bioscience, Inc. to Present at the Jefferies Global Healthcare Conference on June 5, 2024 HOLLISTON, Mass., May 23, 2024 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that Jim Green, Chairman and Chief Executive Officer, and Jennifer Cote, Chief Financial Officer, will be presenting to investors at the Jefferies Global Healthcare Conference at the Marriott Marquis in New York City on June 5, 2024. The Company’s presentation will be 2:00-2:25 PM ET on June 5th. The presentation will be webcast live and can be accessed through the investor relations ...

 PRESS RELEASE

Harvard Bioscience, Inc. to Participate in the Benchmark Healthcare Ho...

Harvard Bioscience, Inc. to Participate in the Benchmark Healthcare House Call Virtual Conference HOLLISTON, Mass., May 16, 2024 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that Jim Green, Chairman and Chief Executive Officer, and Jennifer Cote, Chief Financial Officer, will be participating in the Benchmark Healthcare House Call Virtual Conference on May 22nd, 2024, with a live fireside chat scheduled for 9:00-9:40 am ET. The Company will also be hosting one-on-one meetings with investors in conjunction with the Conference. To register for the presentatio...

 PRESS RELEASE

Harvard Bioscience Announces First Quarter 2024 Financial Results

Harvard Bioscience Announces First Quarter 2024 Financial Results Strong gross margin performance and focus on efficiency to support ongoing investments in growth HOLLISTON, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced financial results for the first quarter ended March 31, 2024. Jim Green, Chairman and CEO, said, “As expected, our first quarter revenues reflect ongoing market headwinds, especially in APAC, amplified by a strong prior year comparison. Despite these headwinds, we were pleased to deliver gross margins of ...

 PRESS RELEASE

Harvard Bioscience Schedules First Quarter 2024 Earnings Conference Ca...

Harvard Bioscience Schedules First Quarter 2024 Earnings Conference Call for May 7, 2024 at 8:00 AM ET HOLLISTON, Mass., April 29, 2024 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for the quarter ended March 31, 2024 before the market opens on May 7, 2024, and will hold a conference call to discuss the results at 8:00 a.m. Eastern Time.  Participants who would like to join the call and ask a question must register . Once registered, you will receive the dial-in numbers and a unique PIN number.  Participants who would like to join the a...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch